drugset / Trial / NCT06059846
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (greater than or equal to (≥)18 years of age) with cUTI or AP.
Timeline
- Start
- 2023-12-21
- Primary completion
- 2025-01-27
- Completion
- 2025-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imipenem-Cilastatin | Unknown | 300 mg | Intravenous |
| Comparator | Imipenem-Cilastatin | Unknown | 400 mg | Intravenous |
| Comparator | Imipenem-Cilastatin | Unknown | 500 mg | Intravenous |
| Subject | TBP-PI-HBr | Unknown | 300 mg | Oral |
| Subject | TBP-PI-HBr | Unknown | 600 mg | Oral |